Drug Delivery Platforms
Controlled release of oral drugs.
Controlled release oral liquid drugs.
Tamper-resistant controlled release formulations of narcotics and other drugs prone to abuse.
Controlled release of injected biologics and small molecules drugs.
Flamel Technologies currently markets Bloxiverz and Vazculep (FDA-approved products), and develops internally products using the Unapproved Marketed Drug strategy and products based on its drug delivery platforms, and products with partners.
As a publicly-held company, Flamel Technologies strives to use its technologies to create extraordinary shareholder value.